Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Samsung Biologics Co Ltd (207940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8221
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities include process development, contract manufacturing, aseptic fill and finish and project management. Samsung Biologics cell culture development process includes upstream, downstream and analytical technology. Samsung Biologics’ provides manufacturing and quality assurance for the clinical and commercial products. The company also provides infrastructure for partnership with other organizations to develop, refine, and distribute the bio-pharmaceutical products. It owns manufacturing facilities for cell culture development, purification, quality control, MSAT laboratory. Samsung Biologics is headquartered in Incheon, South Korea.

Samsung Biologics Co Ltd (207940) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Equity Offering 13
Samsung Biologics Raises USD2.03 Billion in IPO 13
Acquisition 14
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 14
Samsung Biologics Co Ltd – Key Competitors 15
Samsung Biologics Co Ltd – Key Employees 16
Samsung Biologics Co Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
Jul 23, 2018: Samsung BioLogics announces sales of KRW 125.4 billion and profits of KRW 23.7 billion in 2Q 2018 18
Jan 31, 2018: Samsung BioLogics Sales and Profits in 2017 19
Apr 25, 2017: Samsung BioLogics announces its financial results for 1Q 2017 20
Jan 24, 2017: Samsung BioLogics sales and profits in 2016 21
Legal and Regulatory 22
Oct 22, 2018: Samsung BioLogics obtains an Authorized Economic Operator (AEO) certificate 22
Jul 12, 2018: Samsung BioLogics violated accounting standards 23
Jun 21, 2018: Samsung BioLogics Receives Health Canada Approval 24
May 24, 2018: Samsung BioLogics Receives an additional FDA Approval for its world largest Plant’s Production 25
Apr 25, 2018: Samsung BioLogics becomes the first in the South Korean pharma industry to achieve ISO 22301 Certificate 26
Apr 13, 2018: Samsung BioLogics receives the 1st EMA Approval for its Plant No. 2 production 27
Government and Public Interest 28
Oct 17, 2018: Samsung BioLogics may face disciplinary action for alleged accounting breach 28
Other Significant Developments 29
Oct 01, 2018: Samsung BioLogics plant 3 starts production 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
MilliporeSigma to Enter into Agreement with Samsung Biologics 10
AstraZeneca Forms Joint Venture with Samsung Biologics 11
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 12
Samsung Biologics Raises USD2.03 Billion in IPO 13
Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 14
Samsung Biologics Co Ltd, Key Competitors 15
Samsung Biologics Co Ltd, Key Employees 16
Samsung Biologics Co Ltd, Joint Venture 17

List of Figures
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Samsung Biologics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Samsung Biologics Co Ltd (207940):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UCB SA (UCB):医療機器:M&Aディール及び事業提携情報
    Summary UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines …
  • Alere Toxicology Plc:企業の戦略的SWOT分析
    Alere Toxicology Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Cummins Inc.:企業の戦略・SWOT・財務情報
    Cummins Inc. - Strategy, SWOT and Corporate Finance Report Summary Cummins Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Tokmanni Group Oyj (TOKMAN):企業の財務・戦略的SWOT分析
    Tokmanni Group Oyj (TOKMAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • BWX Technologies Inc (BWXT):電力:M&Aディール及び事業提携情報
    Summary BWX Technologies Inc (BWXT) is a specialty manufacturer of nuclear components. It designs, engineers, and manufactures precision naval nuclear components, reactors, and nuclear fuel for the US Government. The company also provides special nuclear materials processing and environmental site r …
  • Energizer Holdings, Inc.:戦略・SWOT・企業財務分析
    Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Energizer Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • HeidelbergCement AG:戦略・SWOT・企業財務分析
    HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report Summary HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • BrainLAB AG:企業の戦略的SWOT分析
    BrainLAB AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Haemonetics Corp (HAE):企業の財務・戦略的SWOT分析
    Haemonetics Corp (HAE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • University of Pennsylvania-医療機器分野:企業M&A・提携分析
    Summary University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, cri …
  • TAP Biosystems Ltd-製薬・医療分野:企業M&A・提携分析
    Summary TAP Biosystems Ltd (TAP), a subsidiary of Sartorius Stedim Biotech GmbH is a medical laboratory that provides laboratory and pharmaceutical equipment. The laboratory offers products such as single-use mini bioreactor systems and automated cell culture systems. It also provides labware, consu …
  • High Peak Royalties Ltd (HPR):企業の財務・戦略的SWOT分析
    High Peak Royalties Ltd (HPR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Cogeco Communications Inc (CCA):企業の財務・戦略的SWOT分析
    Cogeco Communications Inc (CCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Vikas WSP Ltd (VIKASWSP):企業の財務・戦略的SWOT分析
    Vikas WSP Ltd (VIKASWSP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Total Petrochemicals & Refining USA Inc:企業の戦略的SWOT分析
    Total Petrochemicals & Refining USA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Xylem Inc (XYL)-エネルギー分野:企業M&A・提携分析
    Summary Xylem Inc. (Xylem) is a water technology company that designs, manufactures, and service engineered technologies for water industry. The company’s products portfolio includes testing equipment; filtration, disinfection and biological treatment equipment; controls and systems; and water and w …
  • Commonwealth Scientific and Industrial Research Organisation:製薬・医療:M&Aディール及び事業提携情報
    Summary Commonwealth Scientific and Industrial Research Organisation (CSIRO) is a national science agency that conducts research in climate adaptation, bio-security, renewable and energy, farming and food production, and information technology, and mining and manufacturing services, and others. The …
  • Total System Services Inc (TSS):企業の財務・戦略的SWOT分析
    Total System Services Inc (TSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Aimmune Therapeutics Inc (AIMT):企業の財務・戦略的SWOT分析
    Summary Aimmune Therapeutics Inc (Aimmune) formerly Allergen Research Corp is a clinical-stage biopharmaceutical company that develops proprietary product candidates for the treatment of peanut and other food allergies. The company’s lead product candidate AR101 is used to treat the peanut allergy. …
  • Bajaj Allianz General Insurance Company Limited:企業の戦略・SWOT・財務情報
    Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary Bajaj Allianz General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆